Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ME004
- Development stage
- Preclinical
- Lead developer
- Letolab
- Modality
- Peptides
01
Overview
ME004 is a peptide-based amylin analog being developed by Letolab for the treatment of obesity and weight management. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells that plays a significant role in glucose homeostasis and the regulation of satiety. By acting as an agonist at amylin receptors in the brain, ME004 is designed to mimic the effects of endogenous amylin, leading to reduced appetite and decreased food intake. The drug is currently in the IND-enabling stage of development, positioned within Letolab's metabolic disease pipeline alongside other candidates for weight loss and NASH.
02
Targets
AMY receptor (Calcitonin receptor (with ramps))
Beyond the preview
Go deeper on ME004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ME004.